Evidence map›Paper›PMID 40885776›Full record

ArticleScientific reports2025

Selective right heart valve remodelling in a mouse model of carcinoid disease revealed by high-resolution episcopic microscopy.

Gaspard Suc, Mustafa Habib, Sofiane Mohammed, Gregory Franck, Samuel Sitbon, Jacques Callebert, Marine Jullien, Baptiste Bazire, Philippe Ruszniewski, Louis de Mestier and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gaspard Suc *Paris Cité University and Sorbonne Paris Nord University, INSERM, LVTS, Cardiology Department, AP-HP, Bichat Hospital, 75018, Paris, France.
Mustafa Habib *Paris Cité University and Sorbonne Paris Nord University, INSERM, LVTS, Cardiology Department, AP-HP, Bichat Hospital, 75018, Paris, France.
Sofiane Mohammed *Paris Cité University and Sorbonne Paris Nord University, INSERM, LVTS, 75018, Paris, France.
Gregory FranckParis Cité University and Sorbonne Paris Nord University, INSERM, LVTS, 75018, Paris, France.
Samuel SitbonParis Cité University and Sorbonne Paris Nord University, INSERM, LVTS, Cardiology Department, AP-HP, Bichat Hospital, 75018, Paris, France.
Jacques CallebertParis Cité University, INSERM U942, Biochemistry and Molecular Biology Department, AP-HP, Lariboisière Hospital, 75010, Paris, France.
Marine JullienParis Cité University and Sorbonne Paris Nord University, INSERM, LVTS, Cardiology Department, AP-HP, Bichat Hospital, 75018, Paris, France.
Baptiste BazireParis Cité University and Sorbonne Paris Nord University, INSERM, LVTS, Cardiology Department, AP-HP, Bichat Hospital, 75018, Paris, France.
Philippe RuszniewskiParis Cité University, Pancreatology and Digestive Oncology Departement, AP-HP, Beaujon Hospital, 92110, Clichy, France.
Louis de MestierParis Cité University, Pancreatology and Digestive Oncology Departement, AP-HP, Beaujon Hospital, 92110, Clichy, France.
Audrey CailliauParis Cité University and Sorbonne Paris Nord University, INSERM, LVTS, Cardiology Department, AP-HP, Bichat Hospital, 75018, Paris, France.
Lydia DeschampsParis Cité University and Sorbonne Paris Nord University, INSERM, LVTS, Pathological Anatomy and Cytology Department, AP-HP, Bichat Hospital, 75018, Paris, France.
Dimitri ArangalageParis Cité University and Sorbonne Paris Nord University, INSERM, LVTS, Cardiology Department, AP-HP, Bichat Hospital, 75018, Paris, France.
Antonino NicolettiParis Cité University and Sorbonne Paris Nord University, INSERM, LVTS, 75018, Paris, France.
Giuseppina Caligiuri *Paris Cité University and Sorbonne Paris Nord University, INSERM, LVTS, Cardiology Department, AP-HP, Bichat Hospital, 75018, Paris, France.
Jamila Laschet *Paris Cité University and Sorbonne Paris Nord University, INSERM, LVTS, 75018, Paris, France. Jamila.laschet@inserm.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinoid heart disease, a severe complication of neuroendocrine tumors, affects up to 50% of patients and is challenging to treat due to a limited understanding of its mechanisms. The disease is characterized by structural remodeling and thickening of the right heart valves, associated with elevated levels of serotonin (5-HT) released from tumor cells that have spread to the liver. Existing animal models have limitations as they either use mice with compromised immune systems or employ methods that don't consistently evaluate valve changes. We developed an improved experimental model by implanting syngeneic liver-targeted melanoma cells that were genetically engineered to produce 5-HT through the expression of the enzyme tryptophan hydroxylase type 1 (Tph1) in wild-type C57BL/6 mice. We introduced high-resolution episcopic microscopy (HREM) for comprehensive assessment of valve pathology and morphometry. Five weeks after implantation, mice exhibited increased 5-HT/creatinine urinary level ratios and HREM imaging showed selective thickening and structural remodeling of right heart valves (tricuspid and pulmonary), correlating with 5-HT/creatinine urinary level ratio, while left heart valves remained unaffected. Our data suggest that this non-immunosuppressed, right-heart valve restricted model reproduces key features of human carcinoid heart disease and, combined with HREM analysis, provides a valuable platform for studying disease mechanisms and testing potential therapies.

Indexed as

Carcinoid Heart DiseaseHeart ValvesAnimalsCell Line, TumorDisease Models, AnimalMiceMice, Inbred C57BLMicroscopySerotoninTryptophan HydroxylaseSerotoninTph1 protein, mouseTryptophan HydroxylaseAnimal experimentationHeart valves/pathologyHigh-resolution episcopic microscopyMiceSerotonin

Identifiers

PMID40885776
PMCPMC12398488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.